MODULATION THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Phase 1
Recruiting
- Conditions
- Uveal MelanomaMetastatic
- Interventions
- Drug: 38 microCi of 225Ac-MTI-201Drug: 254 microCi of 225Ac-MTI-201Drug: 19 microCi of 225Ac-MTI-201Drug: 152 microCi of 225Ac-MTI-201Drug: 750 microCi of 225Ac-MTI-201Drug: 564 microCi of 225Ac-MTI-201Drug: 4.7 microCi 225Ac-MTI-201Drug: 9.5 microCi of 225Ac-MTI-201Drug: 424 microCi of 225Ac-MTI-201Drug: 76 microCi of 225Ac-MTI-201Drug: 998 microCi of 225Ac-MTI-201Drug: 1327 microCi of 225Ac-MTI-201
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Modulation Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05496686
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath